Hereditary Hemorrhagic Telangiectasia — the hidden cause of stroke in young adults from paradoxical embolism through pulmonary AVMs, in a condition where 30-40% of patients never know they have it until a neurological event occurs.
Whole genome sequencing identifies ENG, ACVRL1, and SMAD4 variants — distinguishing HHT types with different AVM patterns — and establishes the diagnosis that triggers the pulmonary AVM screening that prevents strokes.
Hereditary Hemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant vascular disorder caused by pathogenic variants in genes encoding proteins in the BMP/TGF-β arterial signaling pathway, leading to abnormal blood vessel development with formation of arteriovenous malformations (AVMs). AVMs are direct arteriovenous connections that lack normal capillary beds — they can bleed, cause high-output cardiac failure, and allow venous blood to bypass pulmonary filtration. HHT affects approximately 1 in 5,000-8,000 individuals worldwide. The classic clinical triad — recurrent nosebleeds (epistaxis), mucocutaneous telangiectasias, and AVMs in visceral organs — often allows clinical diagnosis, but AVMs in lung and brain may be asymptomatic until a catastrophic event.
HHT is genetically heterogeneous. Type 1 (ENG — endoglin, chromosome 9q34.11) and type 2 (ACVRL1 — activin receptor-like kinase 1, chromosome 12q13.13) each account for approximately 40-45% of molecularly confirmed HHT. SMAD4 pathogenic variants account for approximately 2% and cause a combined juvenile polyposis/HHT syndrome. Rarer variants in RASA1 and EPHB4 cause a related syndrome. ENG variants are associated with higher rates of pulmonary AVMs (present in approximately 60-80% of HHT1 patients) compared to ACVRL1 (30-40% of HHT2 patients). ACVRL1 variants are associated with a higher rate of hepatic AVMs and pulmonary hypertension.
Pulmonary AVMs are the most immediately dangerous manifestation of HHT. Right-to-left shunting allows paradoxical embolism — venous thrombi, bacteria, or air bubbles that would normally be filtered by the pulmonary capillary bed pass directly into the systemic circulation, causing ischemic stroke, brain abscess, or systemic embolism. The risk is proportional to pulmonary AVM size; AVMs with feeding arteries ≥3mm are treated prophylactically by embolotherapy. An estimated 30-40% of HHT patients with pulmonary AVMs have a stroke or TIA as their first neurological event before the diagnosis is established. Pulmonary AVM screening by transthoracic contrast echocardiography or chest CT — combined with embolotherapy for amenable lesions — is life-saving when initiated at diagnosis.
SMAD4 variants cause a combined juvenile polyposis/HHT phenotype. These patients require GI polyposis surveillance in addition to standard HHT management — a clinical need that is only recognized when the specific SMAD4 genotype is identified.
ENG and ACVRL1 have distinct clinical profiles and AVM site distributions. SMAD4 causes a combined syndrome requiring GI surveillance. Whole genome sequencing identifies all three genes simultaneously and resolves pathogenic large deletions that standard panel sequencing misses.
HHT type determines where AVMs form — and where surveillance must focus
HHT type 1 (ENG) carries higher pulmonary AVM prevalence and requires more aggressive screening by both contrast echocardiography and CT chest. HHT type 2 (ACVRL1) carries higher rates of hepatic AVMs and hepatic involvement, with a subset developing high-output cardiac failure and pulmonary hypertension from liver shunting. This clinical distinction guides organ-specific surveillance intensity and influences treatment decisions — bevacizumab has shown particular efficacy in HHT2 hepatic involvement. Knowing which gene is mutated from a complete molecular diagnosis, rather than relying solely on clinical criteria, enables genotype-tailored surveillance from the outset.
Large ENG and ACVRL1 deletions account for 10-20% of HHT cases — missed by standard sequencing panels
Both ENG and ACVRL1 have documented large genomic deletions in approximately 10-20% of molecularly confirmed HHT families. Standard panel sequencing without copy number variant analysis will miss these rearrangements and report a false-negative result in families where a deletion is the causative variant. A false-negative HHT molecular result in a family where the clinical diagnosis of HHT is strong — multiple nosebleed-affected family members, mucocutaneous telangiectasias, and a history of pulmonary AVM — may delay or prevent cascade genetic testing of at-risk relatives, who then do not receive pulmonary AVM screening and remain at stroke risk. Whole genome sequencing provides both point mutation detection and copy number variant analysis in a single test.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Hereditary Hemorrhagic Telangiectasia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
